Health News Roundup: US FDA declines to approve Supernus' Parkinson's combination again; Trump says abortion laws should be decided by US states and more

The agency began its review into the class of weight loss and diabetes drugs, known as GLP-1 receptor agonists, last July after Iceland's health regulator flagged three cases of patients thinking about suicide or self-harm after using Novo's drugs – diabetes drug Ozempic and weight-loss treatment Saxenda. Exclusive-Synchron, a rival to Musk’s Neuralink, readies large-scale brain implant trial Synchron Inc, a rival to Elon Musk's Neuralink brain implant startup, is preparing to recruit patients for a large-scale clinical trial required to seek commercial approval for its device, the company's chief executive told Reuters.


Devdiscourse News Desk | Updated: 09-04-2024 19:23 IST | Created: 09-04-2024 18:25 IST
Health News Roundup: US FDA declines to approve Supernus' Parkinson's combination again; Trump says abortion laws should be decided by US states and more
Representative Image

Following is a summary of current health news briefs.

US CDC says bird flu risk low, but asks states to be ready with rapid testing

The U.S. Centers for Disease Control and Prevention (CDC) said on Monday bird flu risk to the public remains low even as it asked the state public health officials to be prepared to respond. The agency asked for plans to quickly test and provide treatment to potentially impacted farm workers following positive results among cattle herds.

Pfizer RSV shot meets goals in trial of high-risk adults under age 60

Pfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well tolerated and generated an immune response in higher risk adults under the age of 60 similar to that in older adults, for whom the shot is already approved. Pfizer said it plans to submit its findings from the trial to seek expanded approval of the vaccine in adults ages 18 to 59, but did not give a time frame for when it expects the data to be considered by regulators.

Vatican rejects gender-affirming surgery and surrogacy in new document

The Vatican on Monday reaffirmed its opposition to gender-affirming surgery, "gender theory" and surrogate parenthood, drawing criticism from advocates for LGBTQ Catholics. The declaration by the Vatican's doctrinal office (DDF) comes four months after another document in which it supported blessings for same-sex couples, triggering fierce conservative pushback, especially in Africa.

Siemens's Snabe open to extending his stay as chairman past 2025

Siemens Chairman Jim Hagemann Snabe is open to extending his stint at the German engineering and technology company after his term expires next year, he told Reuters on Tuesday. "At the 2025 Annual General Meeting, I will have been on the Supervisory Board for eleven and a half years. So I could extend my term again, not for four years, but perhaps for one or two years if necessary," Snabe said in an interview.

EU regulator to review reports of suicidal thoughts and weight loss drugs

A European Medicines Agency committee will this week hold a meeting related to its probe into reports of suicidal thoughts after taking diabetes and weight loss drugs such as Novo Nordisk's Ozempic, an agenda showed on Monday. The agency began its review into the class of weight loss and diabetes drugs, known as GLP-1 receptor agonists, last July after Iceland's health regulator flagged three cases of patients thinking about suicide or self-harm after using Novo's drugs – diabetes drug Ozempic and weight-loss treatment Saxenda.

Exclusive-Synchron, a rival to Musk’s Neuralink, readies large-scale brain implant trial

Synchron Inc, a rival to Elon Musk's Neuralink brain implant startup, is preparing to recruit patients for a large-scale clinical trial required to seek commercial approval for its device, the company's chief executive told Reuters. Synchron on Monday plans to launch an online registry for patients interested in joining the trial meant to include dozens of participants, and has received interest from about 120 clinical trial centers to help run the study, CEO Thomas Oxley said in an interview.

Argentina faces rising dengue epidemic risk as mosquitoes hatch early

Mosquitoes are hatching earlier in Argentina and reaching cooler regions than before, as rising temperatures drive the country's worst outbreak of dengue fever and raise the risk of more regular epidemics of the insect-borne virus, scientists said. So far in the 2023/24 season, the South American nation has recorded 232,996 cases of the disease sometime known as "break-bone fever" for the severe muscle and joint pain it can cause, along with high fever, headache, vomiting, and skin rash.

US FDA declines to approve Supernus' Parkinson's combination again

Supernus Pharmaceuticals said on Monday the U.S. FDA declined to approve its drug-device combination to treat movement-related symptoms of Parkinson's disease, sending its shares down 9% in early trade. This is the second time the regulator has refused to approve, dealing a blow to the company's years-long effort to market its pump-based treatment.

Trump says abortion laws should be decided by US states

Republican presidential candidate Donald Trump said on Monday that abortion laws should be determined by U.S. states, stopping short of proposing a national ban that could have imperiled his chances with swing voters in the November election. Trump previously signaled support for a ban beyond 15 weeks of pregnancy but said political considerations were paramount in the first presidential election since the U.S. Supreme Court overturned the landmark 1973 Roe v. Wade decision, ending a nearly 50-year federal right to the procedure.

(With inputs from agencies.)

Give Feedback